For decades, one of the greatest challenges in cancer care has been the simple fact that many cancers do not reveal themselves until they are already advanced.
As physicians, we see the consequences every day. When cancer is found early, treatments are more effective, less invasive and patients have more options including curative treatments. When it is found late, our tools are limited and outcomes are harder on patients, families and the health care system as a whole.
That reality is why a new generation of multi‑cancer early detection tests represents such an important scientific development.
First let us discuss screening and surveillance: Screening is the first test for a disease or cancer, and surveillance is ongoing testing in high-risk individuals. The multi-cancer early detection concept is to advance both risk assessment (for more active surveillance) and also diagnosis, which could end up replacing the need for biopsy or advance imaging in some patients.
Multi-cancer early detection tests are blood-based‑ screening tools designed to detect biological signals associated with multiple types of solid tumors. They are not typical diagnostic tests, nor are they a replacement for established screenings like mammograms or colonoscopies. Instead, they are to be used as a complementary first step, particularly for cancers that currently have no routine screening and surveillance options.
This distinction matters. Today, about 600,000 Americans die of cancer every year, and nearly 70% of those deaths come from cancers that have no recommended screening or surveillance tests. Liver, pancreatic and ovarian cancers are among them. These diseases often progress silently, and by the time symptoms emerge, treatment options are more limited, and survival rates are significantly lower.
Recent clinical studies offer encouraging evidence. In a large multi-center trial that included 13 research sites here in California, multi-cancer early detection testing, used alongside standard screenings, detected more cancers overall, including many that would not have been found through existing methods alone. Notably, more than half of the cancers identified by the multi-cancer early detection test were found at earlier stages, when treatment is more likely to improve both survival and quality of life.
Liver cancer, for example, illustrates how this progress could translate into practice. While surveillance tools, such as ultrasound and alpha-fetoprotein testing are effective for high-risk patients, many may never reach specialty liver care until the disease is advanced. Expanding risk-based detection into primary care could identify patients sooner and trigger timely surveillance and treatment that is not only more effective, but often less invasive.
Scientific progress, however, only benefits patients when policy keeps pace.
This year, Congress passed the Medicare Multi-Cancer Early Detection Screening Coverage Act, led in part by California Rep. Raul Ruiz, a fellow physician who understands firsthand the importance of early detection. The law establishes a clear pathway for Medicare to cover multi-cancer early detection tests once they receive FDA clearance. Without it, access to these screening tools could lag years behind the science, leaving patients unable to benefit even when evidence supports their use.
As a physician, I welcome this progress. But passing a law is only the beginning. The real work now lies in rigorous FDA review, clear clinical guidance and thoughtful implementation.
How these tests are integrated into practice across the entire health care system, not only by physicians, but also by nurse practitioners, physician associates and pharmacists will be critical, particularly as at-home tests become more available. Equally critical is how results are communicated. These decisions will determine whether patients benefit from earlier detection while avoiding unnecessary anxiety or confusion about what the results do and do not mean.
If 2026 is remembered as a turning point in cancer detection, it will be because we paired scientific advancement with responsible policy and sound clinical practice. For the first time, a simple blood draw has the potential to identify dozens of cancers earlier, at a moment when treatment can be more effective, less costly and outcomes can meaningfully improve.
Integrating multi-cancer early detection testing into our screening landscape will require care and clarity. With strong results already demonstrated, we can expect outcomes to improve even further as ongoing research helps us optimize when and how these tests are used. For patients and families across our community, earlier detection is not an abstract scientific goal — it is a chance for more time, more option, and better outcomes.
That is a future worth working toward.
Dr. Robert G. Gish is an adjunct professor at UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, a staff physician at La Maestra Community Health Center, and medical director of the American Pacific Health Foundation.
Want to submit a letter to the editor, guest column or opinion piece? Find our guidelines and submission form here.
Hence then, the article about opinion 2026 could mark turning point for early detection of multiple cancers was published today ( ) and is available on Times of San Diego ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Opinion: 2026 could mark turning point for early detection of multiple cancers )
Also on site :
- Manycore, the first of the Hangzhou ‘Little Dragons’ to go public, pushes ‘spatial intelligence’ as the next wave of AI development
- Invitation to telephone conference concerning Duni AB (publ) interim report 1 January - 31 March 2026
- Wind Advisory issued April 17 at 2:56AM PDT until April 17 at 8:00AM PDT by NWS Los Angeles/Oxnard CA